Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity

INTRODUCTION: Locally advanced basal cell carcinoma (laBCC) has always represented an uncommon, difficult-to-treat form of skin cancer, but approval of the Hedgehog inhibitor (HHI) vismodegib has provided an effective, well-tolerated therapy. While this drug has been shown to be a safe and effective...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Dermatol Ther (Heidelb)
Main Authors: Scalvenzi, Massimiliano, Cappello, Milena, Costa, Claudia, Fabbrocini, Gabriella, Luciano, Mariaantonietta, Villani, Alessia
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer Healthcare 2020
נושאים:
Original Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7211780/
https://ncbi.nlm.nih.gov/pubmed/32240528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-020-00371-1
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים